CAS 179324-69-7
:Bortezomibe
- B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
- Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
- Bortezomib for research
- Bortizomib
- Brotezamide
- Dpba
- Ldp 341
- Mg 341
- Mln 341
- N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
- N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
- NSC 681239
- PS 341 (pharmaceutical)
- Ps 314
- Ps 341
- Radiciol
- Velcade
- Ver mais sinónimos
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
Bortezomib
CAS:Fórmula:C19H25BN4O4Pureza:>98.0%(HPLC)Cor e Forma:White to Almost white powder to crystalPeso molecular:384.24Bortezomib [Optimized for Cell Culture]
CAS:Fórmula:C19H25BN4O4Pureza:>98.0%(HPLC)Cor e Forma:White to Almost white powder to crystalPeso molecular:384.24Bortezomib, 98%
CAS:Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.Fórmula:C19H25BN4O4Pureza:98%Cor e Forma:White to off-white, Powder or crystals or crystalline powderPeso molecular:384.24Bortezomib
CAS:BortezomibFórmula:C19H25BN4O4Pureza:98% (nmr) (Typical Value in Batch COA)Cor e Forma:SolidPeso molecular:384.23719Bortezomib
CAS:Fórmula:C19H25BN4O4Pureza:≥ 98.0%Cor e Forma:White to off-white powder or solidPeso molecular:384.24[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
CAS:Fórmula:C19H25BN4O4Pureza:98%Cor e Forma:SolidPeso molecular:384.2372Bortezomib-D8 (Major)
CAS:Produto ControladoApplications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)Fórmula:C19H17D8BN4O4Cor e Forma:NeatPeso molecular:392.29Bortezomib
CAS:Produto ControladoStability Hygroscopic and Moisture Sensitive
Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);Fórmula:C19H25BN4O4Cor e Forma:NeatPeso molecular:384.24Bortezomib
CAS:Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.Fórmula:C19H25BN4O4Pureza:97.79% - >99.99%Cor e Forma:White SolidPeso molecular:384.237Bortezomib
CAS:((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acidFórmula:C19H25BN4O4Pureza:98%Peso molecular:384.24Bortezomib - Bio-X ™
CAS:Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.Fórmula:C19H25BN4O4Pureza:Min. 95%Cor e Forma:PowderPeso molecular:384.24 g/molBortezomib
CAS:Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.Fórmula:C19H25BN4O4Pureza:Min. 95%Cor e Forma:White PowderPeso molecular:384.24 g/mol












